Abstract. We here report a novel mutation of the thiazide-sensitive Na-Cl cotransporter (TSC) (SLC12A3) gene in a Japanese patient with Gitelman's syndrome (GS). GS is characterized by a renal disorder and is associated with hypokalemia, hypomagnesemia, metabolic alkalosis and hypocalciuria arising from the defective tubular reabsorption of magnesium and potassium. This disease is reportedly caused by mutations in the TSC gene. A 52-year-old man was referred to our hospital because of sleeplessness and tinnitus. He exhibited hypokalemia, hypomagnesemia, hypocalciuria, metabolic alkalosis and hyperreninemic hyperaldosteronism. A renal clearance study revealed that the administration of furosemide decreased chloride reabsorption; however, the ingestion of thiazide failed to decrease chloride reabsorption. A diagnosis of GS was made based on the clinical features, laboratory data and renal function test results. Sequencing of the patient's genomic DNA revealed an A to T transition at the initial codon of exon 1 of the TSC gene (c1A>T). Knowledge of this novel mutation may be helpful for understanding the pathophysiology of GS and the function of TSC as well as for providing genetic counseling.
PATIENTS with Gitelman's syndrome (GS) manifest clinical symptoms of tetany and muscle weakness. GS is characterized by hypokalemic metabolic alkalosis in combination with hypomagnesemia and hypocalciuria and is recognized as a variant of Bartter's syndrome (BS) [1] . Mutations in either bumetamide-sensitive Na-K-2Cl transporter (NKCC2), apical ATP-regulated potassium channel (ROMK), or kidney-specific basolateral chloride channel (CLCNKB) are known to cause BS [2] [3] [4] . In contrast, Simon et al. reported that GS is a homogenous distal tubular disorder that is caused by the mutation of the thiazide-sensitive Na-Cl cotransporter (TSC) gene (SLC12A3) [5] . Mastroianni et al. reported the molecular cloning, expression pattern and chromosomal localization of the human TSC gene [6] . The TSC gene maps to human chromosome 16q13 and contains 26 exons. TSC consists of 12 transmembrane domains and long intracellular aminoand carboxy-terminal regions [7] . The expression of TSC is restricted to the apical membrane of the distal convoluted tubule, where thiazide inhibits sodiumchloride reabsorption [8] .
To date, more than 100 distinct TSC mutations have been identified. Gene analysis is therefore very important for the diagnosis of GS [9] . In Japan, several mutations of the TSC gene have been reported in patients with GS [10] [11] [12] . We here report a novel mutation of the initial codon of the TSC gene in a Japanese patient with GS.
Case Report
A 52-year-old man was referred to our institution for further evaluation because of hypokalemia and hypomagnesemia. The patient had been suffering from sleeplessness and tinnitus, so he was hospitalized for diagnosis and treatment. His parents were nonconsanguineous. He was 159 cm tall, weighed 55.4 kg, and had a body mass index 21.9 kg/m 2 . His blood pressure was 118/72 mmHg. He had no history of tetany, and Chvostek's sign was negative. No abnormal physical findings were found.
The laboratory findings for the patient upon admission are summarized in Table 1 . His serum potassium and magnesium levels were markedly low, and his urinary calcium level was also reduced ( Table  1) . His plasma renin activity and aldosterone concentrations were both elevated. An arterial blood gas analysis revealed the existence of metabolic alkalosis. To determine whether he had GS or BS, we performed a series of clearance studies.
The clearance studies were performed according to a previously described protocol [13] . Briefly, the patient drank water (20 mL/kg body weight) after an overnight fast and then received an intravenous infusion of 0.45% saline. Once the urinary flow reached a rate of 10 mL/ min, either furosemide (20 mg intravenously) or hydrochlorothiazide (100 mg orally) was administered. Clearance was calculated as follows: osmolar clearance (Cosm) = Uosm × V/Posm, where V is the urine volume; the maximal free water clearance (CH 2 O) = V -Cosm; chloride clearance (CCl) = UCl × V/PCl; and distal fractional chloride reabsorption is defined as CH 2 O/(CH 2 O + CCl). The distal fractional chloride reabsorption results are shown in Table 2 . The administration of furosemide decreased chloride reabsorption, while thiazide ingestion failed to decrease chloride reabsorption. These results indicate that the thick ascending limb of Henle's loop, where furosemide works, is intact but that the distal convoluted tubule is impaired in this patient. Thus, a diagnosis of GS was made based on the clinical features, laboratory data and renal function test results.
We then performed a genetic analysis, after obtaining written informed consent. This analysis was approved by the Ethical Committee on human research of Yokohama City University. The TSC gene contains 26 exons [6] . These exons were amplified using polymerase chain reaction (PCR), and the amplified products were subjected to direct sequencing using specific primers according to a previous report [11] . The amplified products were then electrophoresed and sequenced. As shown in Fig. 1 , the antisense sequence of the patient's TSC gene revealed a T to A transition at the initial codon of exon 1 (c1A>T). Thus, the diagnosis of GS was confirmed. Potassium and magnesium were administered orally, and his symptoms greatly improved. 
Discussion
According to papers by Bettinelli et al. [14, 15] , the clinical diagnostic criteria for GS are as follows: hypomagnesemia (<0.65 mmol/L (<1.58 mg/dL)), hypokalemia (<3.6 mmol/L (mEq/L)), and hypocalciuria (molar ratio of urinary calcium to creatinine <0.2 or <0.1). The present case meets these criteria. Furthermore, a renal clearance test using furosemide or thiazide revealed that distal fractional chloride reabsorption was impaired by the administration of furosemide but not by the administration of thiazide in this patient. These results indicate that the thick ascending limb of Henle's loop, where furosemide works, is intact but that the distal convoluted tubule, where thiazide works, is impaired. This finding also supports a diagnosis of GS.
GS was first characterized by Gitelman et al. in 1966 [1] . GS was thought to be a variant of Bartter's syndrome but is now recognized as an autosomal recessive disorder caused by inactivating mutations in the TSC gene [6] . About 100 distinct mutations of the TSC gene have been identified since 1996, when Simon et al. first identified TSC mutations in patients with GS [5] . These mutations include missense, nonsense, frameshift, and splicing-site mutations and are scattered throughout the protein. A specific mutation hot spot has not been reported so far [9] .
This patient had a homogenous missense mutation from ATG to TTG in the initial codon of exon 1 of the TSC gene (Fig. 1) . As GS is an autosomal recessive disorder, both of the patient's parents are thought to have a heterozygous mutation, although we have not confirmed this speculation. As for mutations in exon 1, a nucleotide transition C→T in the 5' UTR of the gene, a 2-bp deletion (nucleotides 45-46), D62N and a 2-bp insertion (263 insCC) have been reported [16] . To the best of our knowledge, the mutation in the present patient is novel.
Functional studies have revealed that many TSC mutant proteins have an impaired plasma membrane routing, leading to the dysfunction of the Na-Cl cotransporter [17, 18] . The functional consequence of the missense mutation of ATG to TTG in the initial codon of exon 1 is unknown. However, because similar mutations in the initiation codon were reported in several genetic diseases [19, 20] , we assume that our mutation (c1A>T) might change amino-acid residues due to alternative initiation of translation at a second, in-frame ATG present 53 codons downstream. Therefore, the missense mutation in the initial codon of TSC in this case may impair the function of TSC. We hope to perform a functional analysis in a subsequent study.
Although GS is an autosomal recessive disorder, cases of heterozygous mutations alone have been reported [21] . Analyses of the TSC gene in the parents and family members of this patient would clarify whether a heterozygous mutation of this gene is responsible for GS in this patient. However, because we have been unable to examine his other family members, we cannot make any conclusion regarding the significance of this mutation in its heterozygous state.
In summary, we have identified a novel mutation (A to T in the initial codon) of the TSC gene in a patient with GS. Knowledge of this novel mutation may be helpful for understanding the pathophysiology of GS and the function of TSC as well as for providing genetic counseling.
